Announced Thu, 25 Jun · 18:21 IST
Jagsonpal Pharma appoints Anil Matai as Independent Director for 5 years
Management Changes View source PDF
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.6%1-day move
₹223.00
prior close
₹222.32
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+2.4+2.7—+7.6+6.5+5.3+6.6+6.7+2.6+0.0———
Up moveDown movePending
AI summary
Jagsonpal Pharmaceuticals has appointed Anil Kumar Matai as an additional Non-Executive Independent Director effective June 25, 2026, for a 5-year term subject to shareholder approval. Matai brings 35 plus years of pharma and life sciences experience, including former roles as CEO of Novartis India and President and MD of Zydus Healthcare. He currently serves as Director General of OPPI.
Likely market impact
Strengthens board with a seasoned pharma industry veteran. Positive for governance, but appointment still needs shareholder approval.